Perceptive Advisors’s Dyne Therapeutics DYN Stock Holding History

Perceptive Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$84.6M	Buy	4,668,839 +1,189,895	+34%	+$20.5M	1.65%	20
2025 Q4	$68M	Buy	3,478,944 +2,938,500	+544%	+$55.6M	1.21%	26
2025 Q3	$6.84M	Sell	540,444 -1,706,946	-76%	-$19.5M	0.2%	68
2025 Q2	$21.4M	Sell	2,247,390 -66,013	-3%	-$727K	0.79%	34
2025 Q1	$24.2M	Buy	2,313,403 +1,770,126	+326%	+$25.3M	0.85%	32
2024 Q4	$12.8M	Sell	543,277 -174,867	-24%	-$5.17M	0.35%	52
2024 Q3	$25.8M	Buy	+718,144	New	+$28.6M	0.55%	46
2021 Q1	–	Sell	-400,000	Closed	-$8.4M	–	147
2020 Q4	$8.4M	Hold	400,000	–	–	0.09%	111
2020 Q3	$8.08M	Buy	+400,000	New	+$8.78M	0.12%	96

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Perceptive Advisors's DYN Position: Q1 2026 in Review

Perceptive Advisors increased its Dyne Therapeutics (DYN) stake by 34% in Q1 2026, buying an estimated $20.5M and bringing the position to 4,668,839 shares worth $84.6M. The position accounts for 1.65% of the portfolio, ranked #20.

Perceptive Advisors first reported a position in DYN in Q3 2020 and has held it in 9 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Perceptive Advisors held 4,668,839 shares of Dyne Therapeutics worth $84.6M as of Q1 2026.
Perceptive Advisors bought 1,189,895 Dyne Therapeutics shares in Q1 2026, an estimated $20.5M.
Dyne Therapeutics made up 1.65% of Perceptive Advisors's portfolio in Q1 2026, its #20 holding.
Perceptive Advisors first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 9 quarters since.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.